Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 3
1999 1
2000 6
2001 15
2002 30
2003 31
2004 43
2005 30
2006 28
2007 28
2008 35
2009 52
2010 43
2011 51
2012 65
2013 42
2014 33
2015 25
2016 27
2017 30
2018 21
2019 7
2020 16
2021 15
2022 17
2023 21
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

670 results

Results by year

Filters applied: . Clear all
Page 1
Olmesartan medoxomil.
Warner GT, Jarvis B. Warner GT, et al. Drugs. 2002;62(9):1345-53; discussion 1354-6. doi: 10.2165/00003495-200262090-00005. Drugs. 2002. PMID: 12076183 Review.
Reductions in seated DBP were greater with olmesartan medoxomil 10 to 20 mg/day than losartan 50 to 100 mg/day. ...Adverse events were infrequent in clinical studies of olmesartan medoxomil and were similar to those attributed to placebo. ...
Reductions in seated DBP were greater with olmesartan medoxomil 10 to 20 mg/day than losartan 50 to 100 mg/day. ...Adverse eve …
Olmesartan medoxomil/amlodipine.
Sanford M, Keam SJ. Sanford M, et al. Drugs. 2009;69(6):717-29. doi: 10.2165/00003495-200969060-00005. Drugs. 2009. PMID: 19405551 Review.
black triangle Olmesartan medoxomil/amlodipine is a fixed-dose combination of olmesartan medoxomil and amlodipine, both established antihypertensive agents. Dose titration with the individual constituent drugs is recommended before switching to the equ …
black triangle Olmesartan medoxomil/amlodipine is a fixed-dose combination of olmesartan medoxomil and amlodipin …
Olmesartan medoxomil: a review of its use in the management of hypertension.
Scott LJ, McCormack PL. Scott LJ, et al. Drugs. 2008;68(9):1239-72. doi: 10.2165/00003495-200868090-00005. Drugs. 2008. PMID: 18547134 Review.
Oral olmesartan medoxomil 10-40 mg once daily is recommended for the treatment of adult patients with hypertension. In those with inadequate BP control using monotherapy, fixed-dose olmesartan medoxomil/hydrochlorothiazide (HCTZ) [Olmetec plus, Benicar …
Oral olmesartan medoxomil 10-40 mg once daily is recommended for the treatment of adult patients with hypertension. In those w …
Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension.
Deeks ED. Deeks ED. Drugs. 2011 Jan 22;71(2):209-20. doi: 10.2165/11206770-000000000-00000. Drugs. 2011. PMID: 21275446 Review.
The antihypertensive agents olmesartan medoxomil, amlodipine and hydrochlorothiazide (HCTZ) are now available as a fixed-dose combination tablet (olmesartan medoxomil/amlodipine/HCTZ). In a 12-week, randomized, double-blind, multicentre trial (TRINITY) …
The antihypertensive agents olmesartan medoxomil, amlodipine and hydrochlorothiazide (HCTZ) are now available as a fixed-dose …
Olmesartan medoxomil: in children and adolescents with hypertension.
Muir VJ, Keating GM. Muir VJ, et al. Drugs. 2010 Dec 24;70(18):2439-47. doi: 10.2165/11206310-000000000-00000. Drugs. 2010. PMID: 21142262 Review.
Patients received olmesartan medoxomil high dose (20 or 40 mg once daily depending on bodyweight) or low dose (2.5 or 5.0 mg once daily depending on bodyweight). ...Oral olmesartan medoxomil was generally well tolerated in children and adolescents with …
Patients received olmesartan medoxomil high dose (20 or 40 mg once daily depending on bodyweight) or low dose (2.5 or 5.0 mg o …
Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Gardner SF, Franks AM. Gardner SF, et al. Ann Pharmacother. 2003 Jan;37(1):99-105. doi: 10.1345/aph.1C197. Ann Pharmacother. 2003. PMID: 12503943 Review.
DATA SYNTHESIS: Olmesartan medoxomil is a competitively priced addition to the class of angiotensin II receptor antagonists. ...Additionally, animal studies indicate that olmesartan medoxomil may prove to be useful treatment for diabetic nephropathy, a …
DATA SYNTHESIS: Olmesartan medoxomil is a competitively priced addition to the class of angiotensin II receptor antagonists. . …
Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR. Brunner HR. Vasc Health Risk Manag. 2006;2(4):327-40. doi: 10.2147/vhrm.2006.2.4.327. Vasc Health Risk Manag. 2006. PMID: 17323586 Free PMC article. Review.
Olmesartan medoxomil had a fast onset of action, with significant between-group differences evident from 2 weeks onwards. ...Olmesartan medoxomil was at least as effective as amlodipine, felodipine and atenolol, and significantly more effective than ca …
Olmesartan medoxomil had a fast onset of action, with significant between-group differences evident from 2 weeks onwards. ... …
Olmesartan medoxomil: an angiotensin II-receptor blocker.
Brousil JA, Burke JM. Brousil JA, et al. Clin Ther. 2003 Apr;25(4):1041-55. doi: 10.1016/s0149-2918(03)80066-8. Clin Ther. 2003. PMID: 12809956 Review.
RESULTS: Olmesartan medoxomil has been reported to be an effective agent for the treatment of hypertension. ...Olmesartan medoxomil was well tolerated. The most commonly reported adverse effect occurring significantly more often with olmesartan …
RESULTS: Olmesartan medoxomil has been reported to be an effective agent for the treatment of hypertension. ...Olmesartan …
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.
Greathouse M. Greathouse M. Vasc Health Risk Manag. 2006;2(4):401-9. doi: 10.2147/vhrm.2006.2.4.401. Vasc Health Risk Manag. 2006. PMID: 17323594 Free PMC article. Review.
In clinical trials, olmesartan medoxomil/HCTZ reduced systolic BP (SBP) and diastolic BP (DBP) to a greater extent than either component as monotherapy. ...Olmesartan medoxomil/HCTZ is generally well tolerated. In conclusion, olmesartan medox …
In clinical trials, olmesartan medoxomil/HCTZ reduced systolic BP (SBP) and diastolic BP (DBP) to a greater extent than either …
Olmesartan medoxomil for the treatment of hypertension in children and adolescents.
Tocci G, Volpe M. Tocci G, et al. Vasc Health Risk Manag. 2011;7:177-81. doi: 10.2147/VHRM.S11672. Epub 2011 Mar 31. Vasc Health Risk Manag. 2011. PMID: 21490943 Free PMC article. Review.
An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension....
An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer ana …
670 results